MCID: ALL006
MIFTS: 58

Allergic Asthma malady

Categories: Respiratory diseases, Immune diseases

Aliases & Classifications for Allergic Asthma

Aliases & Descriptions for Allergic Asthma:

Name: Allergic Asthma 12 25 14 69
Extrinsic Asthma with Acute Exacerbation 12
Extrinsic Asthma with Status Asthmaticus 12
Ige-Mediated Allergic Asthma 69
Extrinsic Asthma 25
Asthma Allergic 52
Atopic Asthma 12

Classifications:



Summaries for Allergic Asthma

Genetics Home Reference : 25 Asthma is a breathing disorder characterized by inflammation of the airways and recurrent episodes of breathing difficulty. These episodes, sometimes referred to as asthma attacks, are triggered by irritation of the inflamed airways. In allergic asthma, the attacks occur when substances known as allergens are inhaled, causing an allergic reaction. Allergens are harmless substances that the body's immune system mistakenly reacts to as though they are harmful. Common allergens include pollen, dust, animal dander, and mold. The immune response leads to the symptoms of asthma. Allergic asthma is the most common form of the disorder.

MalaCards based summary : Allergic Asthma, also known as extrinsic asthma with acute exacerbation, is related to atopy and asthma, and has symptoms including coughing, wheezing and shortness of breath or has_symptom rapid breathing. An important gene associated with Allergic Asthma is IL13 (Interleukin 13), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nitric Oxide and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include t cells, lung and neutrophil, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An asthma that is characterized by symptoms that are triggered by an allergic reaction caused by inhaled allergens such as dust mite allergen, pet dander, pollen and mold. Allergic asthma is airway obstruction and inflammation that is partially reversible with medication. The disease has symptom coughing, has symptom wheezing, has symptom shortness of breath or has symptom rapid breathing, and has symptom chest tightness.

Related Diseases for Allergic Asthma

Diseases related to Allergic Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
id Related Disease Score Top Affiliating Genes
1 atopy 11.2
2 asthma 11.1
3 aspergillosis 10.9
4 dahlberg borer newcomer syndrome 10.4 IL13 IL5
5 myoglobinuria recurrent 10.4 IFNG IL4
6 rhinitis 10.3
7 papillary squamous carcinoma 10.3 IGHE IL4 IL5
8 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 IL4
9 marasmus 10.3 IL4 IL5 RNASE3
10 lactose intolerance 10.3 IL13 IL4 IL5
11 lens-induced iridocyclitis 10.3 IL4 IL5 RNASE3
12 askin's tumor 10.3 IL13 IL4 IL5
13 anterior dislocation of lens 10.3 CCL11 IL4 RNASE3
14 hypercementosis 10.3 CCL5 IL13 IL5
15 urethral intrinsic sphincter deficiency 10.3 IFNG IL4 IL5
16 hyperinsulinism due to glutamodehydrogenase deficiency 10.3 IFNG IGHE IL4
17 gastroschisis abdominal wall defects, included 10.3 IFNG IL5
18 asymptomatic neurosyphilis 10.3 IFNG IL10 IL4
19 brown shrimp allergy 10.3 IL10 IL5 RNASE3
20 israeli tick typhus 10.3 CCL5 IFNG IL13
21 tungiasis 10.3 IFNG IL10 IL4
22 small intestine lymphoma 10.3 IL4R IL5 RNASE3
23 infectious anterior uveitis 10.3 CCL5 IL5 RNASE3
24 centronuclear myopathy 5 10.3 IFNG IL10 IL4
25 neurotic disorder 10.3 IFNG IL10 IL4
26 hemiplegia 10.3 IL10 IL13 IL4R
27 hidradenitis suppurativa 10.3 CCL11 CCL5 IL10
28 multiple mitochondrial dysfunctions syndrome 10.3 IFNG IL10 IL5
29 tularemia 10.3 IFNG IL10 IL4
30 ectodermal dysplasia bartalos type 10.3 IFNG IL10 IL4
31 leukoplakia of penis 10.3 CCL5 IL10 IL4
32 hydrops of gallbladder 10.3 CCL5 IL4 IL5
33 ovarian mucinous neoplasm 10.3 IL13 IL5 TSLP
34 acute myeloid leukemia with recurrent genetic anomaly 10.3 IFNG IL10 IL4
35 thelaziasis 10.3 CCL11 IL13 IL4 IL5
36 lymphoblastic leukemia 10.3 CCL11 IL13 IL4 IL5
37 hypersensitivity vasculitis 10.3 IL4 IL5 STAT6
38 lymphocytic gastritis 10.3 CCL11 IL13 IL4 IL5
39 middle lobe syndrome 10.3 CCL17 IL10 IL5
40 isolated klippel-feil syndrome 10.3 IFNG IGHE IL4 IL5
41 restrictive cardiomyopathy 10.3 IL5 RNASE3
42 pulpitis 10.3 CCL5 IFNG IL10
43 proximal symphalangism 10.3 IFNG IL10 IL4
44 spastic diplegia 10.2 CCL11 IFNG IL13 IL5
45 myiasis 10.2 IFNG IL10 IL4
46 malignant neoplasm of acoustic nerve 10.2 IFNG IL13 IL4
47 coenurosis 10.2 IL4 IL5 STAT6
48 myofibroma 10.2 IFNG IGHE IL10 IL13
49 status epilepticus 10.2 CCL5 IFNG IL4
50 erb-duchenne and dejerine-klumpke palsies 10.2 CCL5 IFNG IL10

Graphical network of the top 20 diseases related to Allergic Asthma:



Diseases related to Allergic Asthma

Symptoms & Phenotypes for Allergic Asthma

Symptoms:

12
  • coughing
  • wheezing
  • shortness of breath or has_symptom rapid breathing
  • chest tightness

MGI Mouse Phenotypes related to Allergic Asthma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 CCL11 CCL17 CCL5 EPX GATA3 IFNG
2 immune system MP:0005387 10.19 IL5 ITK MS4A2 NPSR1 STAT6 TSLP
3 digestive/alimentary MP:0005381 10.06 GATA3 IFNG IL10 IL13 IL17A IL4
4 endocrine/exocrine gland MP:0005379 10.02 IL13 IL17A IL4 IL4R ITK STAT6
5 integument MP:0010771 9.76 STAT6 TSLP GATA3 IFNG IL10 IL13
6 no phenotypic analysis MP:0003012 9.5 ADAM33 GATA3 IFNG IL10 IL13 IL17A
7 respiratory system MP:0005388 9.36 IL5 NPSR1 STAT6 TSLP CCL11 IFNG

Drugs & Therapeutics for Allergic Asthma

Drugs for Allergic Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 471)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 51-43-4 5816
4
Montelukast Approved Phase 4,Phase 3,Phase 2,Phase 1 158966-92-8 5281040
5
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
6
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-23-7 5754 657311
7
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 1 378-44-9 9782
8
Ipratropium Approved Phase 4,Phase 3 22254-24-6, 60205-81-4 43232
9
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
10
Capsaicin Approved Phase 4 404-86-4 1548943
11
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
12
Azelastine Approved Phase 4,Phase 3,Phase 2,Phase 1 58581-89-8 2267
13
Budesonide Approved Phase 4,Phase 2,Phase 3 51333-22-3 63006 5281004
14
Levocetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1 130018-77-8
15
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83881-51-0 2678
16
Loratadine Approved Phase 4,Phase 3,Phase 2,Phase 1 79794-75-5 3957
17
Desloratadine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100643-71-8 124087
18
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 242138-07-4
19
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
20
Ciclesonide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 126544-47-6, 141845-82-1 444033
21
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
22
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
23
Guaifenesin Approved, Vet_approved Phase 4,Phase 3 93-14-1 3516
24
Norepinephrine Approved Phase 4 51-41-2 439260
25
Theophylline Approved Phase 4,Phase 3,Phase 2 58-55-9 2153
26
Mannitol Approved, Investigational Phase 4,Phase 1 69-65-8 453 6251
27
Zinc Approved Phase 4,Phase 1 7440-66-6 32051 23994
28
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
29
Fexofenadine Approved Phase 4,Phase 3,Phase 2,Phase 1 83799-24-0 3348
30
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
31
Prazosin Approved Phase 4 19216-56-9 4893
32
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
33
Doxazosin Approved Phase 4 74191-85-8 3157
34
Glycerol Approved, Experimental Phase 4,Phase 3,Phase 1,Phase 2 56-81-5 753
35
Terbutaline Approved Phase 4,Phase 3 23031-25-6 5403
36
Phenylephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 59-42-7 6041
37
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2 58-61-7 60961
38
Oxymetazoline Approved Phase 4,Phase 3,Phase 2,Phase 1 1491-59-4 4636
39
Zafirlukast Approved, Investigational Phase 4 107753-78-6 5717
40
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
41
Ketotifen Approved Phase 4,Phase 3,Phase 1,Phase 2 34580-14-8, 34580-13-7 3827
42
Diphenhydramine Approved Phase 4,Phase 3,Phase 2,Phase 1 58-73-1, 147-24-0 3100
43
Itraconazole Approved, Investigational Phase 4,Phase 2,Phase 3 84625-61-6 55283
44
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
45
Almotriptan Approved, Investigational Phase 4 154323-57-6, 181183-52-8 123606
46
Hydroxyzine Approved Phase 4 68-88-2 3658
47
Promethazine Approved Phase 4,Phase 3,Phase 2,Phase 1 60-87-7 4927
48
Menthol Approved Phase 4 2216-51-5 16666
49
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
50
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035

Interventional clinical trials:

(show top 50) (show all 1486)
id Name Status NCT ID Phase
1 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4
2 Predicting the Clinical Response to Omalizumab With Anti-IgE Ab Response or Syk Expression in Basophils Unknown status NCT02023151 Phase 4
3 mRNA Expression as a Biomarker of Omalizumab Response Unknown status NCT01584687 Phase 4
4 Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites Unknown status NCT01052610 Phase 4
5 Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4
6 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4
7 Effects of Montelukast in Asthmatic Children With and Without Food Allergy Unknown status NCT01618929 Phase 4
8 Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4
9 POLlinosis and Exhaled Breath Temperature Unknown status NCT01785394 Phase 4
10 Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children Unknown status NCT00172341 Phase 4
11 Bronchiolitis All-study, SE-Norway Unknown status NCT00817466 Phase 4
12 Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence Unknown status NCT02045875 Phase 4
13 Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma Unknown status NCT00576069 Phase 4
14 A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma Unknown status NCT00461812 Phase 4
15 Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma Unknown status NCT00830505 Phase 4
16 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4
17 Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery Unknown status NCT02110654 Phase 4
18 Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis Unknown status NCT00488176 Phase 4
19 The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils Unknown status NCT00673218 Phase 4
20 Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Unknown status NCT00731770 Phase 4
21 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Unknown status NCT00560586 Phase 4
22 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Unknown status NCT01846962 Phase 4
23 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4
24 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4
25 The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Unknown status NCT01243788 Phase 4
26 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4
27 Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease Unknown status NCT01013701 Phase 4
28 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4
29 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Completed NCT00267202 Phase 4
30 Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma Completed NCT00870584 Phase 4
31 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists Completed NCT00670930 Phase 4
32 Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids Completed NCT00691873 Phase 4
33 A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy Completed NCT00639691 Phase 4
34 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma Completed NCT00264849 Phase 4
35 Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy Completed NCT00329381 Phase 4
36 Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma Completed NCT00567476 Phase 4
37 Prevention of Asthma and Allergy by Probiotic Lactobacillus GG Completed NCT00490425 Phase 4
38 Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen Completed NCT00518518 Phase 4
39 The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients) Completed NCT00777764 Phase 4
40 Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair Completed NCT00139152 Phase 4
41 Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma Completed NCT00980707 Phase 4
42 A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy Completed NCT00283504 Phase 4
43 Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Completed NCT00492076 Phase 4
44 A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy Completed NCT01125748 Phase 4
45 Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing Completed NCT00813748 Phase 4
46 Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma Completed NCT00546143 Phase 4
47 Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma Completed NCT00454051 Phase 4
48 A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) Completed NCT00096954 Phase 4
49 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed NCT00495612 Phase 4
50 Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma Completed NCT00490243 Phase 4

Search NIH Clinical Center for Allergic Asthma

Genetic Tests for Allergic Asthma

Anatomical Context for Allergic Asthma

MalaCards organs/tissues related to Allergic Asthma:

39
T Cells, Lung, Neutrophil, Smooth Muscle, Skin, Testes, Myeloid

Publications for Allergic Asthma

Articles related to Allergic Asthma:

(show top 50) (show all 782)
id Title Authors Year
1
Systemic and mucosal pre-administration of recombinant Helicobacter pylori neutrophil-activating protein prevents ovalbumin-induced allergic asthma in mice. ( 28087613 )
2017
2
Bupleurum chinense extract ameliorates an OVA-induced murine allergic asthma through the reduction of the Th2 and Th17 cytokines production by inactivation of NFI_B pathway. ( 28531919 )
2017
3
LAT alleviates Th2/Treg imbalance in an OVA-induced allergic asthma mouse model through LAT-PLC-I^1 interaction. ( 28063403 )
2017
4
Th9 and other IL-9-producing cells in allergic asthma. ( 27858144 )
2017
5
Murine Models of Allergic Asthma. ( 28063042 )
2017
6
Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma. ( 28063043 )
2017
7
Cost effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. ( 28532191 )
2017
8
Trigonella foenum-graecum alleviates airway inflammation of allergic asthma in ovalbumin-induced mouse model. ( 27939889 )
2017
9
Inhibitory effects of l-theanine on airway inflammation in ovalbumin-induced allergic asthma. ( 27908701 )
2017
10
Type 2 innate lymphoid cells: at the cross-roads in allergic asthma. ( 26965110 )
2016
11
Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. ( 27350385 )
2016
12
Regulation and function of anaphylatoxins and their receptors in allergic asthma. ( 27916272 )
2016
13
DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma. ( 27812543 )
2016
14
Inactivated Mycobacterium phlei inhalation ameliorates allergic asthma through modulating the balance of CD4+CD25+ regulatory T and Th17 cells in mice. ( 27803782 )
2016
15
Behavioral impact of maternal allergic-asthma in two genetically distinct mouse strains. ( 27622677 )
2016
16
Overexpression of programmed cell death 5 in a mouse model of ovalbumin-induced allergic asthma. ( 27846830 )
2016
17
Economic analysis of temperature-controlled laminar airflow (TLA) for the treatment of patients with severe persistent allergic asthma. ( 27026803 )
2016
18
A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. ( 26993628 )
2016
19
Imperatorin exerts antiallergic effects in Th2-mediated allergic asthma via induction of IL-10-producing regulatory T cells by modulating the function of dendritic cells. ( 27185659 )
2016
20
Increase of Frequency and Modulation of Phenotype of Regulatory T Cells by Atorvastatin Is Associated with Decreased Lung Inflammatory Cell Infiltration in a Murine Model of Acute Allergic Asthma. ( 28066430 )
2016
21
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. ( 27117315 )
2016
22
Unlike in Children with Allergic Asthma, IgE Transcripts from Preschool Children with Atopic Dermatitis Display Signs of Superantigen-Driven Activation. ( 27183570 )
2016
23
A dual CysLT1/2 antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma. ( 27444660 )
2016
24
Ligustrazine improves blood circulation by suppressing Platelet activation in a rat model of allergic asthma. ( 27362664 )
2016
25
Comorbidity in allergic asthma and allergic rhinitis: functional somatic syndromes. ( 28034321 )
2016
26
Effect of treatment with geraniol on ovalbumin-induced allergic asthma in mice. ( 27117312 )
2016
27
The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma. ( 27435350 )
2016
28
An Overlook to the Characteristics and Roles Played by Eotaxin Network in the Pathophysiology of Food Allergies: Allergic Asthma and Atopic Dermatitis. ( 26861136 )
2016
29
Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma. ( 27322777 )
2016
30
Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life. ( 27489884 )
2016
31
Origin, Localization, and Immunoregulatory Properties of Pulmonary Phagocytes in Allergic Asthma. ( 27047494 )
2016
32
miR-155: A Novel Target in Allergic Asthma. ( 27783037 )
2016
33
Distribution of CD4+CD8+ double positive T cells in a mouse model of allergic asthma. ( 27096807 )
2016
34
Women using bleach for home cleaning are at increased risk of non-allergic asthma. ( 27492540 )
2016
35
Trace Elements Status in Sera of Patients with Allergic Asthma. ( 28070530 )
2016
36
Costs of perennial allergic rhinitis and allergic asthma increase with severity and poor disease control. ( 27886386 )
2016
37
Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. ( 27115376 )
2016
38
Intranasal Administration of Recombinant Mycobacterium smegmatis Inducing IL-17A Autoantibody Attenuates Airway Inflammation in a Murine Model of Allergic Asthma. ( 26974537 )
2016
39
Clinical evaluation of sublingual administration of dust mite drops in the treatment of allergic asthma and allergic rhinitis of children. ( 27831636 )
2016
40
CD4a8_ and CD8a8_ T cells play a central role in a HDM driven model of allergic asthma. ( 27112462 )
2016
41
Increased expression of nuclear factor of activated TA cells 1 drives IL-9-mediated allergic asthma. ( 26993036 )
2016
42
P2Y6 contributes to ovalbumin-induced allergic asthma by enhancing mast cell function in mice. ( 27590515 )
2016
43
Allergen-specific immunotherapy in pediatric allergic asthma. ( 27489785 )
2016
44
Molecular engineering of a therapeutic antibody for Blo t 5-induced allergic asthma. ( 27923562 )
2016
45
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma. ( 27656673 )
2016
46
Scaffolding protein Gab1 regulates myeloid dendritic cell migration in allergic asthma. ( 27811945 )
2016
47
Picroside II Attenuates Airway Inflammation by Downregulating the Transcription Factor GATA3 and Th2-Related Cytokines in a Mouse Model of HDM-Induced Allergic Asthma. ( 27870920 )
2016
48
Challenges in the management of severe allergic asthma in the elderly. ( 27051308 )
2016
49
Cost utility analysis of the SQ(Ar) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting. ( 27610217 )
2016
50
ADRB2 polymorphisms in allergic asthma in Han Chinese children. ( 26633084 )
2016

Variations for Allergic Asthma

Expression for Allergic Asthma

Search GEO for disease gene expression data for Allergic Asthma.

Pathways for Allergic Asthma

Pathways related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 40)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CCL11 CCL5 EPX GATA3 IFNG IGHE
2
Show member pathways
13.84 CCL11 CCL17 CCL5 IL10 IL13 IL17A
3
Show member pathways
13.71 CCL11 CCL17 CCL5 IFNG IL10 IL13
4
Show member pathways
13.61 CCL11 CCL17 CCL5 IFNG IL10 IL13
5
Show member pathways
13.48 CCL11 CCL17 CCL5 IL10 IL13 IL17A
6
Show member pathways
13.4 CCL11 CCL5 GATA3 IFNG IGHE IL10
7
Show member pathways
13.36 CCL11 CCL17 CCL5 IL10 IL13 IL17A
8
Show member pathways
12.87 CCL11 EPX IFNG IL10 IL13 IL17A
9
Show member pathways
12.72 IFNG IGHE IL10 IL4 IL4R ITK
10
Show member pathways
12.66 IGHE IL13 IL4 IL5 ITK MS4A2
11
Show member pathways